Vacina bcg contra tuberculose: efeito protetor e políticas de vacinação Reportar como inadecuado

Vacina bcg contra tuberculose: efeito protetor e políticas de vacinação - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Odimariles Maria Souza Dantas ; Ricardo Ximenes ; Mauricio L Barreto ;Revista de Saúde Pública 2007, 41 1

Autor: Susan M Pereira



Revista de Saúde Pública ISSN: 0034-8910 Universidade de São Paulo Brasil Pereira, Susan M; Souza Dantas, Odimariles Maria; Ximenes, Ricardo; Barreto, Mauricio L Vacina BCG contra tuberculose: efeito protetor e políticas de vacinação Revista de Saúde Pública, vol.
41, núm.
1, septiembre, 2007, pp.
59-66 Universidade de São Paulo São Paulo, Brasil Available in: How to cite Complete issue More information about this article Journals homepage in Scientific Information System Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Non-profit academic project, developed under the open access initiative Rev Saúde Pública 2007;41(Supl.
1) Susan M PereiraI Odimariles Maria Souza DantasII Ricardo XimenesII BCG vaccine against tuberculosis: its protective effect and vaccination policies Mauricio L BarretoI ABSTRACT OBJECTIVE: The BCG vaccine has been in use since 1921, but still arouses controversy and uncertainties.
The objective was to analyze the protective effect of the BCG vaccine in its first and second doses and the accompanying vaccination policies. METHODS: A systematic review of the literature in both English and Spanish was carried out, covering the period 1948 to 2006, using the PubMed database. The main search terms used included BCG vaccine, BCG efficacy, BCG and tuberculosis.
The studies were grouped by design, with the main results from the clinic tests, case-control studies and meta-analyses presented separately. RESULTS: The protective effect of the first dose of the BCG vaccine against tuberculosis in its miliary and meningeal forms is high.
However, the results vary in relation to the pulmonary form of the disease, with some indicating zero effect and others levels of nearly 80%.
Research is being carried out to develop new vaccines that could substitute the BCG or be used as a booster. CONCLUSIONS: There are evidences that the pr...

Documentos relacionados